{"id":979,"date":"2025-01-23T00:00:00","date_gmt":"2025-01-23T00:00:00","guid":{"rendered":"https:\/\/www.lunit.io\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/"},"modified":"2025-10-31T15:59:34","modified_gmt":"2025-10-31T15:59:34","slug":"lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology","status":"publish","type":"media-hub","link":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/","title":{"rendered":"Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology"},"content":{"rendered":"<p><strong><em>Newly published study in collaboration with Japan\u2019s NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions<\/em><\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-2287 size-medium\" src=\"https:\/\/lunit.supremeclients.com\/en\/en\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2-300x249.png\" alt=\"\" width=\"300\" height=\"249\" srcset=\"https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2-300x249.png 300w, https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2-768x637.png 768w, https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png 822w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>\"Lunit SCOPE HER2\", Lunit'sAI-powered solution designed to detect HER2 expression profile (Courtesy of Lunit)<\/p>\n<p>&nbsp;<\/p>\n<p><strong>SEOUL, South Korea, January 23, 2025<\/strong>\u2014 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study in the<em>Journal of Clinical Oncology Precision Oncology<\/em>. Conducted in collaboration with Japan\u2019s National Cancer Center Hospital East (NCCHE), the study reveals how Lunit\u2019s cutting-edge AI-powered pathology solutions, Lunit SCOPE\u00ae HER2 and Lunit SCOPE IO, significantly improve HER2 biomarker evaluation and the prediction of clinical outcomes in metastatic colorectal cancer (mCRC) patients undergoing HER2-targeted therapy.<\/p>\n<p>This study presents findings from the TRIUMPH phase II clinical trial, which evaluated 30 patients with HER2-positive metastatic colorectal cancer treated with dual HER2-targeted therapy using Trastuzumab and Pertuzumab. Lunit\u2019s AI solutions were applied to assess HER2 status and tumor microenvironment (TME) variables, with significant findings:<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Enhanced HER2 Assessment Accuracy<\/strong><\/p>\n<p>Lunit SCOPE HER2 demonstrated 86.7% accuracy compared to pathologist assessments for HER2 immunohistochemistry (IHC), achieving 100% accuracy in identifying HER2 IHC 3+ cases.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Improved Prediction of Treatment Response and Outcomes<\/strong><\/p>\n<p>Patients identified by the AI model as having a high proportion of HER2 IHC 3+ staining tumor cells (AI-H3-high, &gt;50%) exhibited better clinical outcomes than those identified through traditional HER2 evaluation methods:<\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li>Objective Response Rate (ORR): 42.1% (AI-H3-high) vs. 26.7% (overall TRIUMPH trial)<\/li>\n<li>Progression-Free Survival (PFS): 4.4 months (AI-H3-high) vs. 1.4 months (AI-H3-low)<\/li>\n<li>Overall Survival (OS): 16.5 months (AI-H3-high) vs. 4.1 months (AI-H3-low)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Deeper Insights into the Tumor Microenvironment (TME)<\/strong><\/p>\n<p>Using Lunit SCOPE IO, the study performed detailed TME profiling, including lymphocyte, macrophage, and fibroblast densities. Among AI-H3-high patients, those with low stromal TME density (TME-low) achieved the most favorable outcomes:<\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li>ORR: 57.1%<\/li>\n<li>PFS: 5.6 months<\/li>\n<li>OS: 26.0 months<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>The findings underscore the transformative potential of AI-powered pathology tools in precision oncology. By providing a more accurate and detailed evaluation of HER2 status and TME characteristics, Lunit\u2019s solutions can better stratify patients and predict responses to HER2-targeted therapies currently available or in development. This capability may inform more tailored treatment strategies, ultimately improving patient outcomes in mCRC and potentially other HER2-amplified cancers.<\/p>\n<p>\u201cThis study underscores the potential of AI technology to redefine how we evaluate biomarkers and predict treatment responses,\u201d said Dr. Takayuki Yoshino of the National Cancer Center Hospital East, principal investigator of the research. \u201cThe ability to more precisely stratify patients will lead to more personalized treatment options, improving outcomes for patients with HER2-positive metastatic colorectal cancer.\u201d<\/p>\n<p>\u201cThe findings from this study demonstrate how Lunit\u2019s AI-powered solutions, Lunit SCOPE HER2 and Lunit SCOPE IO, can provide clinicians with actionable insights to refine treatment strategies,\u201d said Brandon Suh, CEO of Lunit. \u201cOur continued collaboration with NCCHE showcases the transformative potential of AI in precision oncology.\u201d<\/p>\n<p>&nbsp;<\/p>\n<p>###<\/p>\n<p><strong>About Lunit<\/strong><\/p>\n<p>Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,500 hospitals and medical institutions across 55+ countries.<\/p>\n<p>&nbsp;<\/p>\n<p>Lunit clinical studies have been published in top journals, including the<em>Journal of Clinical Oncology<\/em>and the<em>Lancet Digital Health<\/em>, and presented at global conferences such as the ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more atlunit.io.<\/p>\n","protected":false},"author":3,"featured_media":2287,"parent":0,"template":"","media-hub-type":[35],"class_list":["post-979","media-hub","type-media-hub","status-publish","has-post-thumbnail","hentry","media-hub-type-precision-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology - Lunit<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology - Lunit\" \/>\n<meta property=\"og:description\" content=\"Newly published study in collaboration with Japan\u2019s NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions &quot;Lunit SCOPE HER2&quot;, Lunit&#039;sAI-powered solution designed to detect HER2 expression profile (Courtesy of Lunit) &nbsp; SEOUL, South Korea, January 23, 2025\u2014 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Lunit\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T15:59:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lunit.supremeclients.com\/en\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"822\" \/>\n\t<meta property=\"og:image:height\" content=\"682\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@lunit_ai\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/\",\"url\":\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/\",\"name\":\"Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology - Lunit\",\"isPartOf\":{\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png\",\"datePublished\":\"2025-01-23T00:00:00+00:00\",\"dateModified\":\"2025-10-31T15:59:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#primaryimage\",\"url\":\"https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png\",\"contentUrl\":\"https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png\",\"width\":822,\"height\":682},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lunit.supremeclients.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/#website\",\"url\":\"https:\/\/lunit.supremeclients.com\/en\/\",\"name\":\"Lunit\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lunit.supremeclients.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/#organization\",\"name\":\"Lunit\",\"url\":\"https:\/\/lunit.supremeclients.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lunit.supremeclients.com\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg\",\"contentUrl\":\"https:\/\/lunit.supremeclients.com\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg\",\"width\":189,\"height\":52,\"caption\":\"Lunit\"},\"image\":{\"@id\":\"https:\/\/lunit.supremeclients.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/lunit_ai\",\"https:\/\/www.linkedin.com\/company\/lunit-inc\",\"https:\/\/x.com\/lunitoncology\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology - Lunit","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology - Lunit","og_description":"Newly published study in collaboration with Japan\u2019s NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions \"Lunit SCOPE HER2\", Lunit'sAI-powered solution designed to detect HER2 expression profile (Courtesy of Lunit) &nbsp; SEOUL, South Korea, January 23, 2025\u2014 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics [&hellip;]","og_url":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/","og_site_name":"Lunit","article_modified_time":"2025-10-31T15:59:34+00:00","og_image":[{"width":822,"height":682,"url":"https:\/\/lunit.supremeclients.com\/en\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@lunit_ai","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/","url":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/","name":"Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology - Lunit","isPartOf":{"@id":"https:\/\/lunit.supremeclients.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#primaryimage"},"image":{"@id":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png","datePublished":"2025-01-23T00:00:00+00:00","dateModified":"2025-10-31T15:59:34+00:00","breadcrumb":{"@id":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#primaryimage","url":"https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png","contentUrl":"https:\/\/lunit.supremeclients.com\/wp-content\/uploads\/2025\/01\/Lunit-SCOPE-HER2.png","width":822,"height":682},{"@type":"BreadcrumbList","@id":"https:\/\/lunit.supremeclients.com\/en\/media-hub\/lunit-ai-enhances-precision-in-predicting-outcomes-for-her2-targeted-therapy-in-metastatic-colorectal-cancer-new-study-published-in-jco-precision-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lunit.supremeclients.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology"}]},{"@type":"WebSite","@id":"https:\/\/lunit.supremeclients.com\/en\/#website","url":"https:\/\/lunit.supremeclients.com\/en\/","name":"Lunit","description":"","publisher":{"@id":"https:\/\/lunit.supremeclients.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lunit.supremeclients.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lunit.supremeclients.com\/en\/#organization","name":"Lunit","url":"https:\/\/lunit.supremeclients.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lunit.supremeclients.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/lunit.supremeclients.com\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg","contentUrl":"https:\/\/lunit.supremeclients.com\/en\/wp-content\/uploads\/2025\/10\/Logo-black.svg","width":189,"height":52,"caption":"Lunit"},"image":{"@id":"https:\/\/lunit.supremeclients.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/lunit_ai","https:\/\/www.linkedin.com\/company\/lunit-inc","https:\/\/x.com\/lunitoncology"]}]}},"_links":{"self":[{"href":"https:\/\/lunit.supremeclients.com\/en\/wp-json\/wp\/v2\/media-hub\/979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lunit.supremeclients.com\/en\/wp-json\/wp\/v2\/media-hub"}],"about":[{"href":"https:\/\/lunit.supremeclients.com\/en\/wp-json\/wp\/v2\/types\/media-hub"}],"author":[{"embeddable":true,"href":"https:\/\/lunit.supremeclients.com\/en\/wp-json\/wp\/v2\/users\/3"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lunit.supremeclients.com\/en\/wp-json\/wp\/v2\/media\/2287"}],"wp:attachment":[{"href":"https:\/\/lunit.supremeclients.com\/en\/wp-json\/wp\/v2\/media?parent=979"}],"wp:term":[{"taxonomy":"media-hub-type","embeddable":true,"href":"https:\/\/lunit.supremeclients.com\/en\/wp-json\/wp\/v2\/media-hub-type?post=979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}